No Free Launch: At-Risk Entry by Generic Drug Firms-Reference-Cited by-同舟云学术

No Free Launch: At-Risk Entry by Generic Drug Firms

Published:2022-09-02 Issue:3 Volume:29 Page:301-315
ISSN:1357-1516
Container-title:International Journal of the Economics of Business
language:en
Short-container-title:International Journal of the Economics of Business

Author:

Drake Keith M.¹,He Robert¹,McGuire Thomas G.¹²,Ndikumana Alice³

Affiliation:

1. Greylock McKinnon Associates, Boston, Massachusetts, USA

2. Department of Health Care Policy, Harvard Medical School, National Bureau of Economic Research, Boston, Massachusetts, USA

3. Bates White, Washington, District of Columbia, USA

Funder

Dean’s Initiative Award, Harvard Medical School

Publisher

Informa UK Limited

Subject

Economics and Econometrics,Business, Management and Accounting (miscellaneous)

Link

https://www.tandfonline.com/doi/pdf/10.1080/13571516.2022.2132808

Reference40 articles.

1. AIPLA 2019 Report of the Economic Survey 2021. Prepared under direction of law practice management committee. https://www.ipwatchdog.com/wp-content/uploads/2021/08/AIPLA-Report-of-the-Economic-Survey-Relevant-Excerpts.pdf

2. Altana Pharma AG and Wyeth, Plaintiffs, v. Teva Pharmaceuticals USA, Inc, et al. 2013., Defendants, No. 2:04-cv-02355 (D.N.J.), Opinion, filed May 14,

3. Apotex 2006. Apotex Launches First Generic Plavix®. Press release, August 8. http://www.ptca.org/pr_apotex/20060808.html

4. A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets

5. Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sharpen Your Sword for Litigation: Incumbent Strategic Reaction to the Threat of Entry;Management Science;2024-04-24

2. The Simple Math of Royalties and Drug Competition During the 180-Day Generic Exclusivity Period;Journal of Competition Law & Economics;2024-02-23